25 Sep 2026 The pre|CISION® Platform Wins Research and Development Achievement Award from Pharma Industry Awards UK 2026 Investors | Therapeutics
25 Sep 2026 The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer Therapeutics
16 Sep 2026 Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial Investors | Therapeutics